Well-capitalized into 2026 with ability to
fully fund lead asset EryDex expected through Phase 3 trial under
special protocol assessment (SPA) and to NDA submission
EryDex utilizes autologous intracellular drug
encapsulation (AIDE) technology designed for slow release of
steroids over several weeks without long-term toxicity typically
associated with chronic administration
Potential for rapid expansion of EryDex to
other rare and debilitating disease indications where chronic
steroid treatment is or could become the standard of care
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology
company focused on acquiring, developing, and commercializing
innovative therapeutics that transform patients’ lives, today
announced that the company has entered into an agreement to acquire
EryDel SpA, a privately-held, late-stage biotech company, in a
stock-for-stock upfront exchange and potential downstream milestone
cash payments. EryDel has developed an autologous intracellular
drug encapsulation (AIDE) technology and a Phase 3 lead asset,
EryDex, targeting a rare fatal pediatric neurological disease,
Ataxia-Telangiectasia (A-T), which currently has no approved
treatments. Upon completion of the transaction, EryDel stockholders
will own approximately 16.7% of the combined company (subject to
downward adjustment) and will be entitled to up to $485 million
upon the achievement of development, regulatory, and commercial
milestone payments, with no royalties. The transaction, which has
been unanimously approved by the Boards of Directors of both
companies, is subject to certain regulatory approvals and other
closing conditions and is expected to close in the third quarter of
2023.
Dirk Thye, M.D., Quince’s Chief Executive Officer, said, “We are
highly enthusiastic and optimistic about our acquisition of this
unique drug/device combination technology platform and promising
late-stage clinical asset to drive Quince’s next stage of growth.
EryDel’s proprietary AIDE technology enables the autologous
intracellular encapsulation and delivery of dexamethasone in a
controlled, slow-release manner that has the potential to allow
chronic administration of steroids over many months or years with a
favorable safety profile. This represents a tremendous opportunity
to target not only A-T, but also the potential to expand into
several debilitating rare diseases where chronic steroid treatment
is the standard of care – or could be in the absence of long-term
steroid toxicity. Upon the close of the acquisition, we will
quickly focus our considerable development expertise and financial
resources toward advancing the lead asset EryDex for A-T through a
single global Phase 3 clinical trial under a SPA already in place
with the FDA to an anticipated NDA submission, assuming positive
study results.”
Luca Benatti, EryDel’s Chief Executive Officer, said, “EryDel’s
acquisition by Quince offers the opportunity to advance our
innovative, point-of-care autologous intracellular encapsulation
technology through development to commercialization and to fulfill
our mission to provide the first treatment for patients living with
the devastating disease of A-T. Quince’s effort will be supported
by the encouraging Phase 3 data generated from EryDel’s prior
international study of EryDex, which demonstrated a significant
delay in disease progression in A-T patients and further supported
more than 10 years of safety data. Quince is well-positioned to
advance EryDel’s differentiated AIDE technology and development of
our lead asset EryDex to deliver innovative treatments to patients
in need.”
Transformative Acquisition with Value-Creating Clinical
Milestones
Key highlights of the EryDel acquisition include:
Well-capitalized into 2026 with ability to fully fund lead asset
EryDex expected through Phase 3 clinical trial under SPA and to NDA
submission
- Strong balance sheet with approximately $87.6 million in cash,
cash equivalents, and short term investments (unaudited) as of June
30, 2023, to provide funding for operating requirements into
2026.
- Capital efficient development plan allows for funding of EryDex
through global Phase 3 clinical trial under SPA and, assuming
positive study results, to NDA submission, in addition to pursuing
European regulatory activities related to potential MAA
submission.
- Potential to out-license ex-U.S. regional territories to
provide runway through regulatory approval of EryDex.
Plan to enroll first patient in global Phase 3 trial of EryDex
in second quarter of 2024 with NDA submission targeted by end of
2025
- SPA in place with FDA for a single global Phase 3 clinical
trial of EryDex expected to be sufficient for NDA submission,
assuming positive study results.
- EryDex designated as orphan drug for treatment of A-T from both
the FDA and EMA.
- Phase 3 NEAT (Neurologic Effects of EryDex on
Subjects with A-T) clinical trial is a planned double blind,
randomized, placebo controlled, global efficacy study in
approximately 86 A-T patients aged six to nine years-old with up to
an additional 20 patients aged 10 years or older included for
potential broader label support.
- Primary endpoint, as agreed upon with the FDA, to measure
neurological function based on rescored modified International
Cooperative Ataxia Rating Scale (RmICARS) from baseline to month
six of treatment.
- Secondary endpoints to measure Clinical Global Impression
scores for severity (CGI-S) and change (CGI-C), as well as EuroQol
quality of life scoring.
- Plan to enroll first patient in Phase 3 NEAT clinical trial in
the second quarter of 2024.
- Commercial version of EryKit treatment consumables approved in
Europe and currently under partial clinical hold pending response
to FDA query.
- Target EryDex NDA submission with the FDA by the end of 2025,
assuming positive Phase 3 NEAT study results.
EryDex efficacy and safety profile demonstrated in prior Phase 3
clinical trial of A-T patients
- Pursuing European regulatory activities related to potential
MAA submission of EryDex based on prior Phase 3 clinical
trial.
- Completed largest global interventional study of A-T patients
(N=175) in Phase 3 ATTeST (Ataxia Telangiectasia
Trial with the EryDex SysTem) clinical
trial and open label extension (OLE) (N=104).
- Primary endpoint measured modified International Cooperative
Ataxia Rating Scale (mICARS) score from baseline to month six of
treatment.
- Secondary endpoints measured CGI-C, Quality of Life (QOL), and
Vineland Adaptive Behavior Scales (VABS) scores.
- EryDex high dose treatment arm demonstrated slowed neurological
deterioration in A-T disease progression as measured by mICARS in
intent to treat population (ITT) with statistically significant
effect in six to nine year-old subgroup across multiple
endpoints.
- 12-month safety analysis demonstrated EryDex well-tolerated
with no major adverse events typically associated with chronic
steroid administration.
- Sustained therapeutic effect and favorable safety profile
maintained for more than three additional years in high dose
treatment arm in OLE study, in addition to no steroid related
toxicity observed in patients receiving more than 10 years of
treatment.
- Conformité Européene (CE) mark already obtained in Europe for
drug/device combination and commercial version of EryKit treatment
consumables.
$1+ billion estimated peak global sales opportunity for A-T
indication alone with rapid expansion potential for EryDex to other
rare and debilitating diseases
- A-T population estimated to be approximately 10,000 patients in
the U.S., U.K., and EU4 countries with no currently approved
therapies and $1+ billion estimated peak sales opportunity
globally.
- EryDex for A-T indication holds potential to be first-to-market
with attractive pricing comparables and no known late-stage
competition.
- EryDex designated as orphan drug for A-T treatment from the FDA
and EMA.
- Potential for rapid expansion of EryDex to other rare and
debilitating disease indications where chronic steroid
administration is the standard of care – or could be in the absence
of long-term steroid toxicity.
- AIDE platform capable of expansion to other drugs or biologics,
including enzyme replacement therapy.
- Multi-faceted technology protections create high barriers to
entry with intellectual property exclusivity until at least 2034
globally and at least 2035 in the U.S.
Transaction Details
Under the terms of the acquisition transaction, EryDel will
operate as a wholly owned subsidiary of Quince Therapeutics with
plans to retain EryDel’s corporate and manufacturing presence in
Italy. The integrated company will be led by Dirk Thye, M.D.,
Quince’s Chief Executive Officer and member of the Quince Board of
Directors. In addition, David Lamond remains Chairperson of
Quince’s Board of Directors, which will be expanded by one member
with the addition of EryDel representative Luca Benatti following
the close of the transaction.
Upon completion of the stock-for-stock upfront exchange, EryDel
stockholders will own a maximum of approximately 16.7%, or
7,250,352 shares, of the combined company (subject to downward
adjustment). The transaction agreement includes up to $485 million
in potential total downstream cash payments, including up to $5
million in development milestones, $25 million at NDA acceptance,
$60 million in approval milestones, and $395 million in market and
sales milestones, with no royalties paid to EryDel stockholders.
The transaction will include the assumption of EryDel’s $13 million
(€10 million in principal) European Investment Bank (EIB) loan with
scheduled payments beginning in the second half of 2026.
The transaction, which has been unanimously approved by the
Boards of Directors of both companies, is subject to certain
regulatory approvals and other closing conditions and is expected
to close in the third quarter of 2023.
Financial Statements
Quince has not completed preparation of its financial statements
for the second quarter of 2023. The cash, cash equivalents, and
short term investments presented as of June 30, 2023, are
preliminary and unaudited and are, thus, inherently uncertain and
subject to change. The company is in the process of completing its
customary close and review procedures for the second quarter of
2023, and there can be no assurance that final results for this
period will not differ from these preliminary, unaudited amounts.
The company’s independent registered public accounting firm has not
audited, reviewed, compiled, or performed any procedures with
respect to such preliminary data for the second quarter ended June
30, 2023.
Advisors
MTS Health Partners, L.P. is serving as financial advisor and
Cooley LLP is serving as legal counsel to Quince. Perella Weinberg
Partners is serving as financial advisor and Goodwin Procter LLP
and Clifford Chance LLP are serving as legal counsel to EryDel.
Investor Presentation Available
To learn more about the transaction, investors are encouraged to
access an investor presentation provided by Quince management
detailing the EryDel acquisition, which is currently available for
viewing on the company’s Investor Relations website. Please visit
the Events page under the News & Events heading of Quince’s
Investor Relations website at ir.quincetx.com to access the
presentation.
About Quince Therapeutics
Quince Therapeutics is a biotechnology company focused on
acquiring, developing, and commercializing innovative therapeutics
that transform the lives of patients suffering from debilitating
and rare diseases. For more information, visit www.quincetx.com and
follow Quince Therapeutics on LinkedIn and @Quince_Tx on
Twitter.
About EryDel SpA
EryDel SpA is a global late-stage biotech company aimed at
developing and commercializing therapies for the treatment of rare
diseases delivered by its proprietary red blood cell technology.
Its most advanced product, EryDex, is under late-stage development
for the treatment of Ataxia Telangiectasia (A-T), a rare autosomal
recessive neurological disorder for which no established therapy is
currently available. EryDex is an automated outpatient bedside
technology to ex-vivo encapsulate dexamethasone sodium phosphate
(DSP; a pro-drug) into patient’s red blood cells, which are then
re-infused, allowing for the circulation of controlled, slow
release, low doses of dexamethasone (active drug) over the
subsequent several weeks following treatment. EryDex has received
orphan drug designation for the treatment of A-T both from the U.S.
Food and Drug Administration (FDA) and the European Medicines
Agency (EMA). An international multicenter, Phase 3 clinical trial,
ATTeST, and its open label extension have been successfully
completed. In addition to EryDex, EryDel’s technology platform is
capable of expansion to other drugs or biologics, including enzyme
replacement therapy, and has the potential to support a wide range
of therapeutic opportunities.
Forward-looking Statements
Statements in this news release contain “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 as contained in Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, which are subject to the “safe harbor”
created by those sections. All statements, other than statements of
historical facts, may be forward-looking statements.
Forward-looking statements contained in this news release may be
identified by the use of words such as “believe,” “may,” “should,”
“expect,” “anticipate,” “plan,” “believe,” “estimated,”
“potential,” “intend,” “will,” “can,” “seek,” or other similar
words. Examples of forward-looking statements include, among
others, statements relating to Quince’s acquisition of EryDel; the
timing of the closing of the transaction; the expected benefits of
the transaction, including the continued current and future
clinical development and potential expansion of EryDel assets,
related platform, and related timing and costs; the strategic
development path for EryDex; planned FDA and EMA submissions and
clinical trials and timeline, prospects, and milestone
expectations; the timing and success of the clinical trials and
related data, including plans and the ability to initiate, fund,
conduct and/or complete current and additional studies; the
potential therapeutic benefits, safety, and efficacy of EryDex;
statements about its ability to obtain, and the timing relating to,
further development of EryDex, regulatory submissions and
interactions with regulators; therapeutic and commercial potential;
the integration of EryDel’s business, operations, and employees
into Quince; Quince’s future development plans and related timing;
its cash position and projected cash runway; the company’s focus,
objectives, plans, and strategies; and the ability to execute on
any strategic transactions. Forward-looking statements are based on
Quince’s current expectations and are subject to inherent
uncertainties, risks, and assumptions that are difficult to predict
and could cause actual results to differ materially from what the
company expects. Further, certain forward-looking statements are
based on assumptions as to future events that may not prove to be
accurate. Factors that could cause actual results to differ
include, but are not limited to, the risks and uncertainties
described in the section titled “Risk Factors” in the company’s
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on May 15, 2023, and other reports as
filed with the SEC. Forward-looking statements contained in this
news release are made as of this date, and Quince undertakes no
duty to update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230724507851/en/
Quince Therapeutics: Stacy Roughan Quince Therapeutics,
Inc. Vice President, Corporate Communications & Investor
Relations ir@quincetx.com
Media: Dan Gagnier & Riyaz Lalani Gagnier
Communications quinceGFC@gagnierfc.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Dec 2023 to Dec 2024